The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
about
Heliox inhalation therapy for bronchiolitis in infantsRationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virusSocial, economic, and health impact of the respiratory syncytial virus: a systematic searchImpact of respiratory syncytial virus: the nurse's perspectiveDefining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Incidence of Hospitalization for Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A Population-Based Study Using Validated Health Administrative Data.A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab ProphylaxisRespiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.The burden of respiratory syncytial virus infection in young childrenEvaluation of IgG Antibodies Against Respiratory Syncytial Virus (RSV), and Associated Risk Factors for Severe Respiratory Tract Infections in Pre-School Children in North-Central, Nigeria.Comparison of risk factors between preterm and term infants hospitalized for severe respiratory syncytial virus in the Russian Federation.Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING StudyEpidemiology of respiratory syncytial virus infection in preterm infants.Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort.Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populationsPredictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics.Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.Pathogenesis of respiratory syncytial virus infection in the murine modelA comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).Palivizumab in the prophylaxis of respiratory syncytial virus infection.Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registriesThe Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infantsPalivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Prevention of respiratory syncytial virus infectionBurden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.Role of Parental Smoking in Severe Bronchiolitis: A Hospital Based Case-Control Study.Palivizumab prophylaxis in 'late preterm' newborns.Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
P2860
Q24187117-D2399367-F183-4D13-8570-7EC4BD40347AQ26825438-0CC59EED-B352-4FFE-918F-5957E09C18FBQ26852865-F839AB25-898B-4619-967E-70BDD8692DFBQ27023799-43B55AF4-93EA-4DF0-A4D1-EBD91A6801D4Q28072535-A9773E44-6BEB-464F-AC28-664A2DFF7CF2Q30251560-0CC46BE8-ED7B-4F64-98D0-7F43FBE4595CQ31055892-59F5D038-AEDD-4D80-8C1C-7977B2937DD1Q33390780-8E790FEA-068B-4105-825F-B4637B575B9CQ33582499-317F9E35-056F-4D4E-A056-AD18E570BCE6Q33628327-F2D0755E-1DF4-421A-AC10-A72821664FDDQ33630047-A5D6218C-149C-401B-8DCF-9FC546E38DF2Q34240719-6B78438C-7881-4338-AEDB-3AC75AFF6301Q34313010-791EEF13-2A5C-452A-8281-75082B8E03E8Q34397659-340C780D-3921-48F7-8F26-BA61D0C9DBEBQ34401644-662A406A-1D92-42C2-8110-9C5D4DDC149FQ34648807-CD935A5D-E40E-49A6-86BB-6923485BFF1FQ34884984-EAB5A319-4113-4D94-9384-16660F5FF0D2Q34938343-B829B1DE-EDB2-49EB-9459-BAACC65BAB77Q35075716-308EF66E-CA5A-4407-97DB-BDE8B4C678D7Q35119631-778B85BE-59A3-43D1-9DBA-45D5758D80D4Q35587298-B86F835F-E172-4829-8977-D3CEF44A9E7EQ35673550-4F7977A4-658F-449D-A216-18770FEE4103Q35678345-2A8292D8-AB1D-45B3-879A-ED3343088668Q35892685-6E78CB05-0850-4E47-93BB-33FDB80BB265Q36054311-03B64F5D-0C94-4DCC-95BA-87974D094CB9Q36093377-0B926A6C-F04F-4104-A8E9-2B99C320AB24Q36206766-9E631A4E-20FD-4CE8-B83E-36143FF72665Q36237028-A6BBA33C-AC73-487F-A99A-4A7362FF1F89Q36275397-FCD45693-68D1-41EC-9793-FA4BFEED80A7Q36278040-B72D83BB-53EA-4A5B-A99A-B033CCF8EBADQ36989863-8F40725C-641A-45BB-A581-8869F1BEFCEFQ37056532-C02969ED-6F04-452E-8818-15A27991EF09Q37075237-9892FA68-4BED-47C2-BA08-BE40963E574DQ37290618-DECA6FAA-8EA3-41E6-91FE-A7B1AB39A50AQ37429454-68A50C6A-BE00-4D37-A1A2-6791A0AD4E0CQ37591891-CE564755-0934-4D59-9EE4-83E88FC3E01CQ37710217-02CDD887-AE90-48A6-AB6E-EBDD889C25E0Q37778833-0F8CD287-EF51-454D-A301-3B1B13F87032Q38057771-5411E356-995D-4F51-8238-633E9A1DAB17Q38058838-4CFC3545-4A46-4B49-8D2F-E5BC9801A016
P2860
The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The Pediatric Investigators Co ...... completed weeks of gestation.
@ast
The Pediatric Investigators Co ...... completed weeks of gestation.
@en
type
label
The Pediatric Investigators Co ...... completed weeks of gestation.
@ast
The Pediatric Investigators Co ...... completed weeks of gestation.
@en
prefLabel
The Pediatric Investigators Co ...... completed weeks of gestation.
@ast
The Pediatric Investigators Co ...... completed weeks of gestation.
@en
P2093
P921
P1476
The Pediatric Investigators Co ...... completed weeks of gestation.
@en
P2093
Andrea Michaliszyn
Avash J Singh
Barbara J Law
Bosco Paes
Brian Simmons
Carina Majaesic
Cecil Ojah
David S C Lee
Diana Parison
Georges Caouette
P304
P356
10.1097/01.INF.0000137568.71589.BD
P577
2004-09-01T00:00:00Z